Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System | Synapse
August 27, 2020
Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
Key Points
Key points are not available for this paper at this time.
Abstract
Esketamine may carry a clear potential for serious AEs, which deserves urgent clarification by means of further prospective studies.